[go: up one dir, main page]

PE20181538A1 - Nueva inmunoterapia contra diversos tumores como el cancer de pulmon, incluido el carcinoma de pulmon amicrocitico (nsclc) - Google Patents

Nueva inmunoterapia contra diversos tumores como el cancer de pulmon, incluido el carcinoma de pulmon amicrocitico (nsclc)

Info

Publication number
PE20181538A1
PE20181538A1 PE2018001559A PE2018001559A PE20181538A1 PE 20181538 A1 PE20181538 A1 PE 20181538A1 PE 2018001559 A PE2018001559 A PE 2018001559A PE 2018001559 A PE2018001559 A PE 2018001559A PE 20181538 A1 PE20181538 A1 PE 20181538A1
Authority
PE
Peru
Prior art keywords
amicrocitic
nsclc
immunotherapy against
relates
against various
Prior art date
Application number
PE2018001559A
Other languages
English (en)
Inventor
Toni Weinschenk
Steffen Walter
Jens Fritsche
Colette Song
Harpreet Singh
Original Assignee
Immatics Biotechnologies Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52460698&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20181538(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GBGB1313987.8A external-priority patent/GB201313987D0/en
Priority claimed from GBGB1403297.3A external-priority patent/GB201403297D0/en
Application filed by Immatics Biotechnologies Gmbh filed Critical Immatics Biotechnologies Gmbh
Publication of PE20181538A1 publication Critical patent/PE20181538A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C12N5/0638—Cytotoxic T lymphocytes [CTL] or lymphokine activated killer cells [LAK]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6489—Metalloendopeptidases (3.4.24)
    • C12N9/6491—Matrix metalloproteases [MMP's], e.g. interstitial collagenase (3.4.24.7); Stromelysins (3.4.24.17; 3.2.1.22); Matrilysin (3.4.24.23)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/24—Metalloendopeptidases (3.4.24)
    • C12Y304/24065—Macrophage elastase (3.4.24.65), i.e. metalloelastase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/11—Coculture with; Conditioned medium produced by blood or immune system cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Virology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Toxicology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La presente invencion se refiere a peptidos, acidos nucleicos y celulas para la utilizacion en metodos inmunoterapeuticos. En concreto, la presente invencion se refiere a la inmunoterapia contra el cancer. La presente invencion se refiere, ademas, a epitopos peptidicos de linfocitos T citotoxicos (CTL) asociados a tumor, solos o en combinacion con otros peptidos asociados a tumor que sirven como principios activos farmaceuticos de composiciones vacunales que estimulan respuestas inmunitarias antitumorales. Mas especificamente, la invencion se refiere a peptidos que comprenden la SEQ ID NO: 5 o secuencias variantes homologas en un 80% a esta
PE2018001559A 2013-08-05 2014-08-04 Nueva inmunoterapia contra diversos tumores como el cancer de pulmon, incluido el carcinoma de pulmon amicrocitico (nsclc) PE20181538A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361862213P 2013-08-05 2013-08-05
GBGB1313987.8A GB201313987D0 (en) 2013-08-05 2013-08-05 Novel immunotherapy against several tumors, such as lung cancer including NSCLC
GBGB1403297.3A GB201403297D0 (en) 2014-02-25 2014-02-25 Novel immunotherapy against several tumors, such as lung cancer, including NSCLC

Publications (1)

Publication Number Publication Date
PE20181538A1 true PE20181538A1 (es) 2018-09-26

Family

ID=52460698

Family Applications (3)

Application Number Title Priority Date Filing Date
PE2015002616A PE20160717A1 (es) 2013-08-05 2014-08-04 Nueva inmunoterapia contra diversos tumores como el cancer de pulmon, incluido el carcinoma de pulmon amicrocitico (nsclc)
PE2020000409A PE20201284A1 (es) 2013-08-05 2014-08-04 Nueva inmunoterapia contra diversos tumores como el cancer de pulmon, incluido el carcinoma de pulmon amicrocitico (nsclc)
PE2018001559A PE20181538A1 (es) 2013-08-05 2014-08-04 Nueva inmunoterapia contra diversos tumores como el cancer de pulmon, incluido el carcinoma de pulmon amicrocitico (nsclc)

Family Applications Before (2)

Application Number Title Priority Date Filing Date
PE2015002616A PE20160717A1 (es) 2013-08-05 2014-08-04 Nueva inmunoterapia contra diversos tumores como el cancer de pulmon, incluido el carcinoma de pulmon amicrocitico (nsclc)
PE2020000409A PE20201284A1 (es) 2013-08-05 2014-08-04 Nueva inmunoterapia contra diversos tumores como el cancer de pulmon, incluido el carcinoma de pulmon amicrocitico (nsclc)

Country Status (28)

Country Link
US (3) US20160168200A1 (es)
EP (10) EP3613427B1 (es)
JP (1) JP2016527293A (es)
KR (9) KR102217680B1 (es)
CN (1) CN105377290B (es)
AU (10) AU2014304544B2 (es)
BR (1) BR112016000810A2 (es)
CA (4) CA3073256A1 (es)
CL (1) CL2016000227A1 (es)
CR (4) CR20200139A (es)
DK (2) DK3456339T3 (es)
EA (1) EA035362B1 (es)
ES (1) ES2764406T3 (es)
HU (1) HUE047079T2 (es)
IL (1) IL243788B (es)
LT (1) LT3030255T (es)
MX (1) MX389568B (es)
NZ (2) NZ733168A (es)
PE (3) PE20160717A1 (es)
PH (1) PH12015502638A1 (es)
PL (1) PL3030255T3 (es)
PT (1) PT3030255T (es)
RS (1) RS59861B1 (es)
SG (4) SG11201510580UA (es)
SI (1) SI3030255T1 (es)
TW (10) TWI777198B (es)
UA (1) UA122661C2 (es)
WO (1) WO2015018805A1 (es)

Families Citing this family (75)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10704021B2 (en) 2012-03-15 2020-07-07 Flodesign Sonics, Inc. Acoustic perfusion devices
PT3456339T (pt) * 2013-08-05 2021-12-09 Immatics Biotechnologies Gmbh Nova imunoterapia contra vários tumores, tais como cancro do pulmão, incluindo cpnpc
WO2015105955A1 (en) 2014-01-08 2015-07-16 Flodesign Sonics, Inc. Acoustophoresis device with dual acoustophoretic chamber
KR20240151873A (ko) * 2015-03-17 2024-10-18 이매틱스 바이오테크놀로지스 게엠베하 췌장암 및 기타 암에 대한 면역요법에서의 사용을 위한 펩티드 및 펩티드의 조합
GB201504502D0 (en) * 2015-03-17 2015-04-29 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against pancreatic cancer and other cancers
GB201505305D0 (en) 2015-03-27 2015-05-13 Immatics Biotechnologies Gmbh Novel Peptides and combination of peptides for use in immunotherapy against various tumors
FI3273986T3 (fi) 2015-03-27 2024-02-07 Immatics Biotechnologies Gmbh Uusia peptidejä ja peptidien yhdistelmiä käytettäväksi immunoterapiassa eri syöpiä vastaan
GB201505585D0 (en) * 2015-03-31 2015-05-13 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides and scaffolds for use in immunotherapy against renal cell carinoma (RCC) and other cancers
TWI772927B (zh) * 2015-03-31 2022-08-01 德商英麥提克生物技術股份有限公司 用於腎細胞癌(rcc)免疫治療的新型肽和肽組合物和支架
GB201507030D0 (en) 2015-04-24 2015-06-10 Immatics Biotechnologies Gmbh Immunotherapy against lung cancers, in particular NSCLC
US11377651B2 (en) 2016-10-19 2022-07-05 Flodesign Sonics, Inc. Cell therapy processes utilizing acoustophoresis
US11708572B2 (en) 2015-04-29 2023-07-25 Flodesign Sonics, Inc. Acoustic cell separation techniques and processes
JP6985153B2 (ja) * 2015-05-06 2021-12-22 イマティクス バイオテクノロジーズ ゲーエムベーハー 結腸直腸がん（ｃｒｃ）およびその他のがんに対する免疫療法で使用するための新規ペプチドおよびペプチドとそのスキャフォールドとの組み合わせ
GB201507719D0 (en) 2015-05-06 2015-06-17 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides and scaffolds thereof for use in immunotherapy against colorectal carcinoma (CRC) and other cancers
PE20180670A1 (es) * 2015-05-20 2018-04-19 Broad Inst Inc Neoantigenos compartidos
CA2989483A1 (en) * 2015-06-19 2016-12-22 Immatics Biotechnologies Gmbh Peptides and combination of peptides for use in immunotherapy and methods for generating scaffolds for the use against pancreatic cancer and other cancers
CN108026154B (zh) 2015-07-01 2022-03-08 伊玛提克斯生物技术有限公司 用于卵巢癌和其他癌症免疫治疗的新型肽和肽组合物
GB201511546D0 (en) 2015-07-01 2015-08-12 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers
MD3319985T2 (ro) * 2015-07-06 2021-01-31 Immatics Biotechnologies Gmbh Noi peptide și combinații de peptide pentru utilizare în imunoterapie împotriva cancerului esofagian și a altor cancere
MY189596A (en) * 2015-07-15 2022-02-18 Immatics Biotechnologies Gmbh A novel peptides for use in immunotherapy against epithelial ovarian cancer and other cancers
GB201513921D0 (en) 2015-08-05 2015-09-23 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against prostate cancer and other cancers
GB201515321D0 (en) * 2015-08-28 2015-10-14 Immatics Biotechnologies Gmbh Novel peptides, combination of peptides and scaffolds for use in immunotherapeutic treatment of various cancers
US10159726B2 (en) 2015-08-28 2018-12-25 Immatics Biotechnologies Gmbh Peptides, combination of peptides and scaffolds for use in immunotherapeutic treatment of various cancers
CN115925806A (zh) 2015-08-28 2023-04-07 伊玛提克斯生物技术有限公司 用于各种癌症免疫治疗的新型肽、肽组合物和支架
HK1258386A1 (zh) 2015-10-05 2019-11-08 Immatics Biotechnologies Gmbh 用於小细胞肺癌和其他癌症免疫治疗的肽和肽组合物
GB201517538D0 (en) 2015-10-05 2015-11-18 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against small cell lung cancer and other cancers
KR20170049024A (ko) * 2015-10-28 2017-05-10 숙명여자대학교산학협력단 ANKs1a 단백질 발현 또는 활성 억제제를 유효성분으로 포함하는 암 예방 또는 치료용 조성물 및 이의 스크리닝 방법
GB201521746D0 (en) 2015-12-10 2016-01-27 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against CLL and other cancers
IL298653A (en) 2015-12-11 2023-01-01 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against various cancers
GB201521894D0 (en) 2015-12-11 2016-01-27 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against various cancers
US10383896B2 (en) 2015-12-11 2019-08-20 Immatics Biotechnologies Gmbh Peptides and combination of peptides for use in immunotherapy against various cancers
AU2016369519B2 (en) 2015-12-16 2023-04-20 Seattle Project Corp. Neoantigen identification, manufacture, and use
GB201522667D0 (en) * 2015-12-22 2016-02-03 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against breast cancer and other cancers
SG10202111399YA (en) 2015-12-22 2021-11-29 Immatics Biotechnologies Gmbh Peptides and combination of peptides for use in immunotherapy against breast cancer and other cancers
GB201602918D0 (en) * 2016-02-19 2016-04-06 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against NHL and other cancers
GB201603987D0 (en) 2016-03-08 2016-04-20 Immatics Biotechnologies Gmbh Uterine cancer treatments
GB201604458D0 (en) 2016-03-16 2016-04-27 Immatics Biotechnologies Gmbh Peptides and combination of peptides for use in immunotherapy against cancers
JP6989136B2 (ja) * 2016-04-06 2022-01-05 イマティクス バイオテクノロジーズ ゲーエムベーハー Ａｍｌおよびその他のがんに対する免疫療法において使用するための新規ペプチドおよびペプチドの組み合わせ
CA3021159A1 (en) * 2016-04-21 2017-10-26 Immatics Biotechnologies Gmbh Immunotherapy against melanoma and other cancers
US11214789B2 (en) 2016-05-03 2022-01-04 Flodesign Sonics, Inc. Concentration and washing of particles with acoustics
JP7075125B2 (ja) 2016-05-25 2022-05-25 イマティクス バイオテクノロジーズ ゲーエムベーハー 標的としてのおよび胆嚢がんおよび胆管がんおよびその他のがんに対する免疫療法で使用するための新規ペプチド、ペプチド組み合わせ
GB201609193D0 (en) 2016-05-25 2016-07-06 Immatics Biotechnologies Gmbh Novel peptides, combination of peptides as targets for use in immunotherapy against gallbladder cancer and cholangiocarcinoma and other cancers
US10868749B2 (en) * 2016-07-26 2020-12-15 Motorola Mobility Llc Method and apparatus for discovering neighborhood awareness networking devices based on presence
NZ750479A (en) * 2016-08-17 2021-12-24 Immatics Biotechnologies Gmbh T cell receptors and immune therapy using the same
TWI796299B (zh) 2016-08-26 2023-03-21 德商英麥提克生物技術股份有限公司 用於頭頸鱗狀細胞癌和其他癌症免疫治療的新型肽和支架
WO2018057858A1 (en) 2016-09-23 2018-03-29 Memorial Sloan Kettering Cancer Center Determinants of cancer response to immunotherapy
WO2018058490A1 (zh) * 2016-09-30 2018-04-05 武汉华大吉诺因生物科技有限公司 Col14a1衍生的肿瘤抗原多肽及其应用
KR20190083671A (ko) * 2016-12-01 2019-07-12 난토믹스, 엘엘씨 종양 항원성 처리 및 발현(tumor antigenicity processing and presentation)
EP4317432A3 (en) 2016-12-08 2024-04-17 Immatics Biotechnologies GmbH T cell receptors with improved pairing
DE102016123893A1 (de) 2016-12-08 2018-06-14 Immatics Biotechnologies Gmbh T-Zellrezeptoren mit verbesserter Bindung
WO2018170313A1 (en) * 2017-03-16 2018-09-20 Advaxis, Inc. Methods and compositions for increasing efficacy of vaccines
SG11201909058WA (en) * 2017-04-10 2019-10-30 Immatics Biotechnologies Gmbh Peptides and combination of peptides for use in immunotherapy against leukemias and other cancers
WO2018200921A1 (en) * 2017-04-28 2018-11-01 Chung Shan Medical University Peptides for cancer treatment
TW201907937A (zh) 2017-05-08 2019-03-01 美商葛利史東腫瘤科技公司 阿爾法病毒新抗原載體
US10800823B2 (en) 2017-07-07 2020-10-13 Immatics Biotechnologies Gmbh Peptides and combination of peptides for use in immunotherapy against lung cancer, including NSCLC, SCLC and other cancers
CA3068852A1 (en) 2017-07-07 2019-01-10 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against lung cancer, including nsclc, sclc and other cancers
EP4576103A3 (en) 2017-10-10 2025-08-27 Gritstone bio, Inc. Neoantigen identification using hotspots
GB201717578D0 (en) * 2017-10-26 2017-12-13 Univ College Cardiff Consultants Ltd Novel T-cell receptor
AU2018373154B2 (en) 2017-11-22 2025-08-07 Seattle Project Corp. Reducing junction epitope presentation for neoantigens
KR102439221B1 (ko) 2017-12-14 2022-09-01 프로디자인 소닉스, 인크. 음향 트랜스듀서 구동기 및 제어기
DE102018107224A1 (de) 2018-02-21 2019-08-22 Immatics Biotechnologies Gmbh Peptide und Kombinationen von Peptiden nicht-kanonischen Ursprungs zur Verwendung in der Immuntherapie gegen verschiedene Krebsarten
TW202016131A (zh) * 2018-05-16 2020-05-01 德商英麥提克生物技術股份有限公司 用於抗癌免疫治療的肽
AU2019275072A1 (en) * 2018-05-23 2021-01-21 Seattle Project Corp. Shared antigens
CN110627895B (zh) * 2018-06-25 2021-03-23 北京大学 肺癌特异性tcr及其分析技术和应用
US10925947B2 (en) * 2018-06-29 2021-02-23 Immatics Biotechnologies Gmbh A*03 restricted peptides for use in immunotherapy against cancers and related methods
EP3946440A4 (en) * 2019-04-02 2023-04-19 The General Hospital Corporation Methods to enhance t cell regeneration
JP7457733B2 (ja) 2019-05-30 2024-03-28 グリットストーン バイオ インコーポレイテッド 改変アデノウイルス
US20220273714A1 (en) * 2019-07-19 2022-09-01 The Regents Of The University Of California T-cell receptors and methods of use thereof
CN111020024A (zh) * 2019-12-05 2020-04-17 复旦大学附属眼耳鼻喉科医院 Tlr9的应用
CN111808908A (zh) * 2020-06-18 2020-10-23 华中科技大学同济医学院附属协和医院 一种促脑胶质瘤耐药的gaMSCs亚群的检测方法
EP4255465A4 (en) * 2020-12-07 2025-02-26 Iogenetics, LLC. Bystander protein vaccines
US20230404967A1 (en) * 2020-12-07 2023-12-21 The Trustees Of Indiana University Methods to sensitize cancer cells to immune attack using atractylenolide i
CN113881707B (zh) * 2021-10-25 2023-07-14 中国人民解放军军事科学院军事医学研究院 调控脐带间充质干细胞免疫抑制作用的产品、方法及用途
CN113969264B (zh) * 2021-11-29 2023-12-08 中南大学 Cog5基因敲除的人胚胎干细胞系、构建方法及应用
CN115125203B (zh) * 2022-07-08 2023-10-27 珠海贝索细胞科学技术有限公司 一种Th2细胞体外培养方法

Family Cites Families (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8212000B2 (en) * 1970-02-11 2012-07-03 Immatics Biotechnologies Gmbh Tumor-associated peptides binding promiscuously to human leukocyte antigen (HLA) class II molecules
US4440859A (en) 1977-05-27 1984-04-03 The Regents Of The University Of California Method for producing recombinant bacterial plasmids containing the coding sequences of higher organisms
US4704362A (en) 1977-11-08 1987-11-03 Genentech, Inc. Recombinant cloning vehicle microbial polypeptide expression
YU44186B (en) 1978-12-22 1990-04-30 Biogen Nv Process for obtaining recombinant dnk molecules
US4530901A (en) 1980-01-08 1985-07-23 Biogen N.V. Recombinant DNA molecules and their use in producing human interferon-like polypeptides
US4342566A (en) 1980-02-22 1982-08-03 Scripps Clinic & Research Foundation Solid phase anti-C3 assay for detection of immune complexes
US4678751A (en) 1981-09-25 1987-07-07 Genentech, Inc. Hybrid human leukocyte interferons
US4766075A (en) 1982-07-14 1988-08-23 Genentech, Inc. Human tissue plasminogen activator
US4582800A (en) 1982-07-12 1986-04-15 Hoffmann-La Roche Inc. Novel vectors and method for controlling interferon expression
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4757006A (en) 1983-10-28 1988-07-12 Genetics Institute, Inc. Human factor VIII:C gene and recombinant methods for production
US4677063A (en) 1985-05-02 1987-06-30 Cetus Corporation Human tumor necrosis factor
US4810648A (en) 1986-01-08 1989-03-07 Rhone Poulenc Agrochimie Haloarylnitrile degrading gene, its use, and cells containing the gene
US4897445A (en) 1986-06-27 1990-01-30 The Administrators Of The Tulane Educational Fund Method for synthesizing a peptide containing a non-peptide bond
ES2138662T3 (es) 1993-06-03 2000-01-16 Therapeutic Antibodies Inc Produccion de fragmentos de anticuerpos.
AUPM322393A0 (en) 1993-12-24 1994-01-27 Austin Research Institute, The Mucin carbohydrate compounds and their use in immunotherapy
DK0879282T3 (da) 1996-01-17 2003-10-20 Imp College Innovations Ltd Immunterapi ved anvendelse af cytotoksiske T-lymfocytter (CTL)
US5849589A (en) 1996-03-11 1998-12-15 Duke University Culturing monocytes with IL-4, TNF-α and GM-CSF TO induce differentiation to dendric cells
US6406705B1 (en) 1997-03-10 2002-06-18 University Of Iowa Research Foundation Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
US20040191260A1 (en) 2003-03-26 2004-09-30 Technion Research & Development Foundation Ltd. Compositions capable of specifically binding particular human antigen presenting molecule/pathogen-derived antigen complexes and uses thereof
WO2001072768A2 (en) 2000-03-27 2001-10-04 Technion Research And Development Foundation Ltd. Single chain class i major histo-compatibility complexes, constructs encoding same and methods of generating same
JP4439808B2 (ja) 2000-06-05 2010-03-24 アルター・バイオサイエンス・コーポレーション Ｔ細胞レセプター融合体および結合体ならびにそれらの使用方法
US7919467B2 (en) * 2000-12-04 2011-04-05 Immunotope, Inc. Cytotoxic T-lymphocyte-inducing immunogens for prevention, treatment, and diagnosis of cancer
CA2457065A1 (en) * 2001-08-13 2003-02-27 Dana-Farber Cancer Institute, Inc. Periostin-based diagnostic assays
US6992176B2 (en) 2002-02-13 2006-01-31 Technion Research & Development Foundation Ltd. Antibody having a T-cell receptor-like specificity, yet higher affinity, and the use of same in the detection and treatment of cancer, viral infection and autoimmune disease
CA2476625A1 (en) 2002-02-20 2003-08-28 Dyax Corp. Mhc-peptide complex binding ligands
WO2004018633A2 (en) * 2002-08-20 2004-03-04 The Government Of The United States Of America As Represented By The Secretary, Department Of Healthand Human Services Abca13 nucleic acids and proteins, and uses thereof
JP4436319B2 (ja) 2002-10-09 2010-03-24 メディジーン リミテッド 単鎖組換えｔ細胞レセプター
DE60327795D1 (de) 2002-11-09 2009-07-09 Immunocore Ltd T zell rezeptor "display"
GB0304068D0 (en) 2003-02-22 2003-03-26 Avidex Ltd Substances
KR100535326B1 (ko) * 2004-01-20 2005-12-09 한국생명공학연구원 줄기 세포로부터 자연살해 세포로의 분화 조절용 유전자를유효성분으로 포함하는 분화 조절제
CN104072614B (zh) * 2005-07-08 2017-04-26 生物基因Ma公司 抗-αvβ6 抗体及其用途
ATE388164T1 (de) 2005-09-05 2008-03-15 Immatics Biotechnologies Gmbh Tumor-assoziierte peptide, welche an unterschiedliche menschliche leukozytenantigene der klasse ii binden
DK1760089T3 (da) * 2005-09-05 2009-11-16 Immatics Biotechnologies Gmbh Tumor-associeret peptides bindende til human leukocyte antigen (HLA) class I eller II molecules og relateret anti-cancer vaccine
CA2636449A1 (en) * 2006-02-22 2007-08-30 Philogen S.P.A. Vascular tumor markers
US20080107668A1 (en) * 2006-08-30 2008-05-08 Immunotope, Inc. Cytotoxic t-lymphocyte-inducing immunogens for prevention, treatment, and diagnosis of cancer
CA2694771A1 (en) * 2007-07-27 2009-02-05 Immatics Biotechnologies Gmbh Composition of tumour-associated peptides and related anti-cancer vaccine
WO2009036246A2 (en) * 2007-09-14 2009-03-19 Immunotope, Inc. Immunogens that induce cytotoxic t-lymphocytes and their use in prevention, treatment, and diagnosis of cancer
MX2010005282A (es) * 2007-11-13 2010-08-31 Teva Pharma Anticuerpos humanizados contra tl1a.
US7996174B2 (en) * 2007-12-18 2011-08-09 Teradyne, Inc. Disk drive testing
EP2262530A4 (en) * 2008-03-03 2012-12-05 Dyax Corp Metalloproteinase-12 TIE PROTEINS
WO2009126271A1 (en) * 2008-04-11 2009-10-15 China Synthetic Rubber Corporation Methods, agents and kits for the detection of cancer
EP2113253B1 (en) 2008-04-30 2010-03-31 Immatics Biotechnologies GmbH Novel formulations of tumour-associated peptides binding to human leukocyte antigen (HLA) class I or II molecules for vaccines
TWI526219B (zh) * 2008-06-19 2016-03-21 腫瘤療法 科學股份有限公司 Ｃｄｃａ１抗原決定位胜肽及含此胜肽的疫苗
ES2638579T3 (es) * 2008-08-29 2017-10-23 Symphogen A/S Composiciones de anticuerpos recombinantes contra el receptor del factor de crecimiento epidérmico
SI2172211T1 (sl) * 2008-10-01 2015-03-31 Immatics Biotechnologies Gmbh Sestavek s tumorjem povezanih peptidov in zadevnih cepiv proti raku za zdravljenje glioblastoma (GBM) in drugih vrst raka
WO2010045388A2 (en) * 2008-10-14 2010-04-22 Dyax Corp. Use of mmp-9 and mmp-12 binding proteins for the treatment and prevention of systemic sclerosis
EP2221063A1 (en) * 2009-02-20 2010-08-25 Ganymed Pharmaceuticals AG Methods and compositions for diagnosis and treatment of cancer
CA2762082C (en) 2009-05-15 2018-06-19 Pacific Edge Biotechnology Limited Markers for detection of gastric cancer
US20110033516A1 (en) * 2009-08-06 2011-02-10 Medical University Of South Carolina Methods and compositions for bone healing by periostin
US8281198B2 (en) 2009-08-07 2012-10-02 Via Technologies, Inc. User-initiatable method for detecting re-grown fuses within a microprocessor
US20120270807A1 (en) * 2009-10-23 2012-10-25 Marsault Eric Macrocyclic inhibitors of serine protease enzymes
TWI485245B (zh) * 2010-01-25 2015-05-21 Oncotherapy Science Inc 經修飾之ｍｅｌｋ胜肽及含此胜肽之疫苗
KR101378919B1 (ko) 2010-01-28 2014-04-14 포항공과대학교 산학협력단 혈액으로부터 직접 폐암 진단 및 폐암의 서브타입 진단이 가능한 마커를 선별하는 시스템 생물학적 방법 및 이로부터 선별된 혈액으로부터 직접 폐암 진단 및 폐암 서브타입 진단이 가능한 마커
GB201004551D0 (en) * 2010-03-19 2010-05-05 Immatics Biotechnologies Gmbh NOvel immunotherapy against several tumors including gastrointestinal and gastric cancer
GB201004575D0 (en) * 2010-03-19 2010-05-05 Immatics Biotechnologies Gmbh Composition of tumor associated peptides and related anti cancer vaccine for the treatment of gastric cancer and other cancers
GB201006360D0 (en) 2010-04-16 2010-06-02 Immatics Biotechnologies Gmbh Method for differentially quantifying naturally processed HLA-restricted peptides for cancer, autoimmune and infectious diseases immunotherapy development
GB201009222D0 (en) * 2010-06-02 2010-07-21 Immatics Biotechnologies Gmbh Improved cancer therapy based on tumour associated antigens derived from cyclin D1
WO2012056407A1 (en) 2010-10-26 2012-05-03 Technion Research & Development Foundation Ltd. Antibodies which bind soluble t-cell receptor ligands
US9028810B2 (en) * 2010-12-20 2015-05-12 Ajou University Industry—Academic Cooperations Foundatin Composition for inducing migration of neural stem cells containing periostin as effective ingredient
WO2013057586A1 (en) 2011-10-19 2013-04-25 Oslo Universitetssykehus Hf Compositions and methods for producing soluble t - cell receptors
GB201319446D0 (en) * 2013-11-04 2013-12-18 Immatics Biotechnologies Gmbh Personalized immunotherapy against several neuronal and brain tumors

Also Published As

Publication number Publication date
CR20210464A (es) 2021-10-26
AU2020220045B2 (en) 2021-11-25
CA3020939C (en) 2023-01-03
KR102317816B1 (ko) 2021-10-26
TW202041520A (zh) 2020-11-16
ES2764406T3 (es) 2020-06-03
TWI777197B (zh) 2022-09-11
KR102213556B1 (ko) 2021-02-05
AU2020220039B2 (en) 2021-05-20
TWI819228B (zh) 2023-10-21
IL243788A0 (en) 2016-04-21
EP3613427B1 (en) 2025-01-15
HK1222121A1 (zh) 2017-06-23
TWI777195B (zh) 2022-09-11
KR20200122419A (ko) 2020-10-27
TW202041515A (zh) 2020-11-16
TW201506043A (zh) 2015-02-16
EP3616710B1 (en) 2025-01-15
KR102098327B1 (ko) 2020-04-08
SG10202002608WA (en) 2020-04-29
KR20200078681A (ko) 2020-07-01
TWI714869B (zh) 2021-01-01
KR102211542B1 (ko) 2021-02-02
US20170202937A1 (en) 2017-07-20
EP3613427A1 (en) 2020-02-26
TWI777196B (zh) 2022-09-11
KR20210008169A (ko) 2021-01-20
NZ714163A (en) 2017-07-28
AU2020220041B2 (en) 2021-11-25
KR102098329B1 (ko) 2020-04-09
SG10202002612PA (en) 2020-05-28
TW202041521A (zh) 2020-11-16
KR20160038889A (ko) 2016-04-07
CA3073394A1 (en) 2015-02-12
TW202041516A (zh) 2020-11-16
AU2020220042B2 (en) 2021-11-25
CR20200139A (es) 2020-09-02
MX2016001426A (es) 2016-05-05
EP3456339B1 (en) 2021-10-20
TW202041517A (zh) 2020-11-16
AU2020220045A1 (en) 2020-09-03
TWI776192B (zh) 2022-09-01
IL243788B (en) 2019-10-31
AU2020220044B2 (en) 2021-11-25
KR20180105754A (ko) 2018-09-28
EP3616708A1 (en) 2020-03-04
KR102217680B1 (ko) 2021-02-18
NZ733168A (en) 2020-04-24
TW202041519A (zh) 2020-11-16
EP3456339A2 (en) 2019-03-20
KR20200123266A (ko) 2020-10-28
DK3030255T3 (da) 2020-01-20
CN105377290B (zh) 2019-09-03
SG10201802399WA (en) 2018-04-27
CR20160018A (es) 2016-06-08
CR20180508A (es) 2019-02-27
PE20201284A1 (es) 2020-11-24
RS59861B1 (sr) 2020-03-31
KR20200122418A (ko) 2020-10-27
CN105377290A (zh) 2016-03-02
BR112016000810A2 (pt) 2017-12-12
CA3073256A1 (en) 2015-02-12
CL2016000227A1 (es) 2016-08-05
CA2912500C (en) 2021-08-24
WO2015018805A1 (en) 2015-02-12
EP3456339A3 (en) 2019-03-27
AU2020220042A1 (en) 2020-09-03
EP3030255A1 (en) 2016-06-15
LT3030255T (lt) 2020-01-27
PE20160717A1 (es) 2016-07-21
EP3616707A1 (en) 2020-03-04
AU2020220044A1 (en) 2020-09-03
TWI777198B (zh) 2022-09-11
AU2018200389A1 (en) 2018-02-08
AU2014304544B2 (en) 2017-10-26
KR20200122417A (ko) 2020-10-27
KR102213551B1 (ko) 2021-02-05
AU2020220040B2 (en) 2021-11-25
CA3020939A1 (en) 2015-02-12
KR102213554B1 (ko) 2021-02-05
EP3616709B1 (en) 2025-01-15
PH12015502638A1 (en) 2016-03-07
TW202041522A (zh) 2020-11-16
TWI777194B (zh) 2022-09-11
EP3616709A1 (en) 2020-03-04
SI3030255T1 (sl) 2020-02-28
UA122661C2 (uk) 2020-12-28
AU2020220043B2 (en) 2021-11-25
US20170319675A1 (en) 2017-11-09
AU2014304544A1 (en) 2015-12-03
PL3030255T3 (pl) 2020-05-18
KR20180107295A (ko) 2018-10-01
EA201690016A1 (ru) 2016-05-31
TW201900669A (zh) 2019-01-01
AU2020220038B2 (en) 2021-11-25
AU2020220041A1 (en) 2020-09-03
EP3616710A1 (en) 2020-03-04
KR102213552B1 (ko) 2021-02-05
HUE047079T2 (hu) 2020-04-28
AU2018200389B2 (en) 2020-07-16
SG11201510580UA (en) 2016-02-26
TWI775117B (zh) 2022-08-21
EP3616711A1 (en) 2020-03-04
MX389568B (es) 2025-03-20
TW202041518A (zh) 2020-11-16
EP3030255B1 (en) 2019-10-09
US9943579B2 (en) 2018-04-17
AU2020220040A1 (en) 2020-09-03
CA2912500A1 (en) 2015-02-12
US10071148B2 (en) 2018-09-11
EP3578196A1 (en) 2019-12-11
AU2020220039A1 (en) 2020-09-03
EP3616708B1 (en) 2025-01-08
AU2020220043A1 (en) 2020-09-03
EA035362B1 (ru) 2020-06-02
JP2016527293A (ja) 2016-09-08
PT3030255T (pt) 2020-01-15
EP3616711B1 (en) 2025-01-15
EP3616712A1 (en) 2020-03-04
DK3456339T3 (da) 2021-12-06
AU2020220038A1 (en) 2020-09-03
US20160168200A1 (en) 2016-06-16
TWI636065B (zh) 2018-09-21

Similar Documents

Publication Publication Date Title
PE20181538A1 (es) Nueva inmunoterapia contra diversos tumores como el cancer de pulmon, incluido el carcinoma de pulmon amicrocitico (nsclc)
PH12021551208A1 (en) Novel immunotherapy against several tumors, such as lung cancer, including nsclc
MX2016014711A (es) Inmunoterapia novedosa contra varios tumores de la sangre, con la leucemia mielogena aguda (lma).
TW201613956A (en) Novel immunotherapy against several tumors of the blood, in particular chronic lymphoid leukemia (CLL)
MX379423B (es) Inmunoterapia personalizada contra diversos tumores cerebrales y neuronales.
GB201004575D0 (en) Composition of tumor associated peptides and related anti cancer vaccine for the treatment of gastric cancer and other cancers
MX2010001088A (es) Composicion de peptidos asociados a tumor y vacunas relacionadas contra el cancer.
MX2019013163A (es) Inmunoterapia novedosa contra varios tumores de la sangre, con la leucemia mielogena aguda (lma).
AR118181A2 (es) Inmunoterapia contra diversos tumores como el cáncer de pulmón, incluido el carcinoma de pulmón amicrocítico (nsclc)
AR113131A2 (es) Inmunoterapia contra diversos tumores como el cáncer de pulmón, incluido el carcinoma de pulmón amicrocítico (nsclc)
MX2019013161A (es) Inmunoterapia personalizada contra diversos tumores cerebrales y neuronales.
MY194244A (en) Novel Immunotherapy Against Several Tumors, Such as Lung Cancer, Including Nsclc
MY194241A (en) Novel Immunotherapy Against Several Tumors, Such as Lung Cancer, Including NSCLC
MY193910A (en) Novel immunotherapy against several tumors, such as lung cancer, including nsclc
MY194653A (en) Novel immunotherapy against several tumors, such as lung cancer, including nsclc
EA202090816A2 (ru) Новый метод иммунотерапии нескольких видов опухолей, таких как рак легкого, включая нмрл